Select Page

January 13, 2021

In order to maximize the value of and access to cannabis-based pharmaceuticals, organizations must ask themselves key strategic questions.​

We are pleased to share our recently published Health Intelligence report, “Maximizing the Value of Cannabis-Based Pharmaceuticals”, which argues that if companies with the ambition to develop cannabis-based pharmaceuticals want to maximize value of and access to their products, it is critical that evidence is generated in a strategic manner to justify health claims. 

We explore three key requirements to maximize value for cannabis-based pharmaceuticals for patients, prescribers and payers:

  • Relevance: Is my product truly relevant to patient and health system needs both now and in the future?
  • Recognition: How can I differentiate my product’s attributes in a manner that will be recognized by payers, systems and patients?
  • Rapidity: What decisive actions will get the product to market in as rapid a manner as possible?

Access the full report here.